nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

11.01.2023 | Original Article

Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis

verfasst von: Akemi Tokutsu, Yosuke Okada, Akira Kurozumi, Kenichi Tanaka, Satoshi Kubo, Yoshiya Tanaka

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Langerhans cell histiocytosis (LCH) is a condition characterized by proliferation of Langerhans cells and wide-range pathologies, ranging from single granulomatous lesions to multi-organ involvement, associated with tissue destruction. LCH pathogenesis remains obscure although association with interleukin (IL)-17A has been reported. We report here a case that illustrates the potential pathogenic role of helper T17 (Th17) cells in LCH-related bone destruction.

Materials and Methods

The patient was a 66-year-old woman. The clinical course included craniectomy and bone mass excision in X-9, diagnosis of LCH confirmed by histopathology, followed by 26-month chemotherapy. In August X, the patient was diagnosed with complete central diabetes insipidus. Symptoms improved after treatment with desmopressin. Pituitary magnetic resonance imaging showed swelling extending from the suprasellar region to the pituitary stalk, suggestive of LCH recurrence. This was followed by chemotherapy combined with mercaptopurine hydrate.

Results

Subsequent peripheral blood lymphocyte analysis showed marked increase in activated Th17 cells (CXCR3⁻CXCR6⁺ CD4⁺ T cells). Double staining for CD4 and IL-17 by immunofluorescence of pathological tissue samples obtained during temporal bone mass excision, which confirmed the diagnosis of LCH in X-9, showed areas of combined presence of CD4-positive cells and IL-17-positive cells. Chemotherapy resulted in size reduction of the pituitary lesion and decrease in peripheral blood-activated Th17 cells.

Conclusions

We found abundant peripheral blood-activated Th17 cells and high percentages of IL-17-producing cells in osteolytic bone lesions in LCH. This finding, together with the decrease in peripheral blood-activated Th17 cells following chemotherapy, suggests the potential involvement of activated Th17 cells in LCH-related osteolysis.

Nur mit Berechtigung zugänglich

Liechtenstein L (1953) Histiocytosis X: integration of eosinophilic granuloma, “Letterer-Siwe disease”, and ”Schuller-Christian dis- ease” as related manifestations of a single nosologic entity. AMA Arch Pathol 56:84–102

Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C et al (2013) Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 8:72. https://doi.org/10.1186/1750-1172-8-72CrossRefPubMedPubMedCentral

Lian C, Lu Y, Shen S (2016) Langerhans cell histiocytosis in adults: a case report and review of the literature. Oncotarget 7:18678–18683. https://doi.org/10.18632/oncotarget.7892CrossRefPubMedPubMedCentral

Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F (1997) Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 28:9–14. https://doi.org/10.1002/(sici)1096-911x(199701)28:1%3c9::aid-mpo3%3e3.0.co;2-pCrossRefPubMed

Grana N (2014) Langerhans cell histiocytosis. Cancer Control 21:328–334. https://doi.org/10.1177/107327481402100409CrossRefPubMed

Cao XX, Duan MH, Zhao AL, Cai H, Chen J et al (2022) Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis. Am J Hematol 97:203–208. https://doi.org/10.1002/ajh.26412. (Epub 2021 Nov 23)CrossRefPubMed

Malpas JS (1998) Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Am 12:259–268. https://doi.org/10.1016/s0889-8588(05)70509-8CrossRefPubMed

Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K et al (2017) Peripheral Immunophenotyping identifies three subgroups based on T Cell heterogeneity in lupus patients. Arthritis Rheumatol 69:2029–2037. https://doi.org/10.1002/art.40180CrossRefPubMed

Maecker HT, McCoy JP, Nussenblatt R (2012) Standardizing immunophenotyping for the human immunology project. Nat Rev Immunol 12:191–200. https://doi.org/10.1038/nri3158CrossRefPubMedPubMedCentral

10.

Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H et al (2016) Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol 104:99–109. https://doi.org/10.1007/s12185-016-1993-3CrossRefPubMed

11.

Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E (1999) Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94:4195–4201PubMed

12.

Kobayashi M, Tojo A (2018) Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci 109:3707–3713. https://doi.org/10.1111/cas.13817CrossRefPubMedPubMedCentral

13.

Ismail MB, Åkefeldt SO, Lourda M, Gavhed D, Aricò M et al (2020) High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis. Cytokine 126:154877. https://doi.org/10.1016/j.cyto.2019.154877CrossRefPubMed

14.

Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM (2008) Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180:214–221. https://doi.org/10.4049/jimmunol.180.1.214CrossRefPubMed

15.

Aggarwal S, Gurney AL (2002) IL-17: Prototype member of an emerging cytokine family. J Leukoc Biol 71:1–8CrossRefPubMed

16.

Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21:467–476. https://doi.org/10.1016/j.immuni.2004.08.018CrossRefPubMed

17.

Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A et al (2011) Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans. J Immunol 186:2602–2612. https://doi.org/10.4049/jimmunol.1003370CrossRefPubMed

18.

Kamizono J, Okada Y, Shirahata A, Tanaka Y (2002) Bisphosphonate induces remission of refractory osteolysis in Langerhans cell histiocytosis. J Bone Miner Res 17:1926–1928. https://doi.org/10.1359/jbmr.2002.17.11.1926CrossRefPubMed

19.

Oh Y, Morimoto A, Shioda Y, Imamura T, Kudo K, Imashuku S, Japan LCH Study Group (2014) High serum osteopontin levels in pediatric patients with high risk Langerhans cell histiocytosis. Cytokine 70:194–197. https://doi.org/10.1016/j.cyto.2014.07.002CrossRefPubMed

20.

Li N, Cui L, Ma H, Gong Z, Lian H et al (2020) Osteopontin is highly secreted in the cerebrospinal fluid of patient with posterior pituitary involvement in Langerhans cell histiocytosis. Int J Lab Hematol 42:788–795. https://doi.org/10.1111/ijlh.13304CrossRefPubMed

21.

Coury F, Annels N, Rivollier A, Olsson S, Santoro A et al (2008) Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 14:81–87. https://doi.org/10.1038/nm1694CrossRefPubMed

Titel: Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis
verfasst von: Akemi Tokutsu
Yosuke Okada
Akira Kurozumi
Kenichi Tanaka
Satoshi Kubo
Yoshiya Tanaka
Publikationsdatum: 11.01.2023
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 2/2023
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01397-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis

Abstract

Introduction

Materials and Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Materials and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids

Impaired function of skeletal stem cells derived from growth plates in ovariectomized mice

Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study

Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis

Effect of vitamin D administration on muscle function improvement depending on vitamin D sufficiency status

Periostin splice variants affect craniofacial growth by influencing chondrocyte hypertrophy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin